Summary
38 / 100 · Bulios Score
What speaks for it
- Revenue grew by 23% a year over the last 3 years.
- The share price is below the Bulios Fair Price.
What to watch
- The company made a loss over the last 12 months.
- Earnings per share swing sharply from year to year.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
The company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
SlowlyRevenue (USD)
Diluted EPS (USD)
Revenue fell by 1.2% a year over 5 years. Over the last 3 years it grew by 23% a year.
Growth in detailDoes it make money?
ReasonablyOver the last 12 months it made a loss of $49.0M.
Profitability in detailIs it financially healthy?
Banks and insurers work with their customers' money, so their debt is judged differently; see the health section for their capital figures.
Financial health in detailDoes it pay a dividend?
High, at risk- Yield
- 9.27%
You receive $1.50 per share a year. The payout is more than the company can comfortably cover.
Dividends in detailWhat do analysts expect?
Neutral- Buy 0
- Hold 2
- Sell 0
Today's price within the analysts' price targets
The average target of $17.5 is 8.2% above today's price. 0.0% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2024By product
- Government Services 68%
- Healthcare Services 32%
By region
The company reports no revenue by region.
Government Services brings in 68% of revenue.
Segments in detail